Boston Scientific Corporation (NYSE:BSX) Shares Bought by Private Advisor Group LLC

Private Advisor Group LLC lifted its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 10.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 38,274 shares of the medical equipment provider's stock after purchasing an additional 3,734 shares during the period. Private Advisor Group LLC's holdings in Boston Scientific were worth $3,861,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Colonial Trust Co SC lifted its position in shares of Boston Scientific by 1,625.0% during the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 260 shares during the last quarter. Investment Management Corp VA ADV purchased a new stake in shares of Boston Scientific during the 4th quarter worth $25,000. Sunbeam Capital Management LLC purchased a new stake in shares of Boston Scientific during the 4th quarter worth $26,000. Ameriflex Group Inc. acquired a new stake in Boston Scientific during the 4th quarter worth $31,000. Finally, Fourth Dimension Wealth LLC acquired a new stake in Boston Scientific during the 4th quarter worth $36,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Price Performance

BSX stock traded down $0.14 during trading on Friday, reaching $106.07. 5,875,124 shares of the company were exchanged, compared to its average volume of 7,847,640. The company has a market cap of $156.92 billion, a P/E ratio of 63.14, a PEG ratio of 2.67 and a beta of 0.68. Boston Scientific Corporation has a 52-week low of $71.88 and a 52-week high of $108.94. The stock's 50 day moving average price is $103.58 and its 200 day moving average price is $101.55. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.88 and a current ratio of 1.45.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.39%. The firm's revenue was up 22.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.62 earnings per share. As a group, analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,314 shares of the firm's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the completion of the transaction, the executive vice president directly owned 22,235 shares of the company's stock, valued at $2,269,304.10. This trade represents a 43.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 56,372 shares of the firm's stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $102.88, for a total transaction of $5,799,551.36. Following the transaction, the executive vice president directly owned 178,342 shares of the company's stock, valued at approximately $18,347,824.96. This trade represents a 24.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 457,144 shares of company stock valued at $47,296,288. Company insiders own 0.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Oppenheimer lifted their price target on shares of Boston Scientific from $110.00 to $118.00 and gave the stock a "market perform" rating in a research note on Thursday. Robert W. Baird lifted their price target on shares of Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a research note on Thursday. Barclays lifted their price target on shares of Boston Scientific from $125.00 to $133.00 and gave the stock an "overweight" rating in a research note on Thursday. Citigroup reiterated a "buy" rating and set a $125.00 price target (up from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. Finally, Raymond James Financial lifted their price objective on shares of Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a research note on Thursday. Two research analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, Boston Scientific has an average rating of "Buy" and a consensus price target of $117.50.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.